Država: Singapur
Jezik: angleščina
Source: HSA (Health Sciences Authority)
PEGINTERFERON ALFA-2B
MSD PHARMA (SINGAPORE) PTE. LTD.
L03AB10
120 mcg/0.5 ml
INJECTION, POWDER, FOR SOLUTION
SUBCUTANEOUS
Prescription Only
MSD INTERNATIONAL GMBH (SINGAPORE BRANCH)
2003-08-29
S-CCDS-MK4031-ALL-072013 Peg-Intron® CLEARCLICK Pre-filled Pen Powder and Solvent for Solution for Injection Brand of peginterferon alfa-2b FOR SUBCUTANEOUS ADMINISTRATION DESCRIPTION: Peg-Intron CLEARCLICK Pre-filled Pen is a single dose presentation available in strengths of 50 mcg, 80 mcg, 100 mcg, 120 mcg, and 150 mcg powder and solvent for solution for injection in pre-filled pens. Peginterferon alfa-2b is a conjugation of recombinant interferon alfa-2b with monomethoxy polyethylene glycol. When reconstituted with solvent , each Peg-Intron CLEARCLICK Pre-filled Pen provides 0.5 ml of solution containing either 50 mcg, 80 mcg, 100 mcg, 120 mcg or 150 mcg. Peg-Intron CLEARCLICK Pre-filled Pen also contains as excipients anhydrous disodium phosphate, dihydrate sodium dihydrogen phosphate, sucrose and polysorbate 80. The solvent provided for parenteral use is sterile water for injection. The deliverable volume from each Peg-Intron CLEARCLICK Pre-filled Pen is 0.5 ml. An overfill is included for proper dispensing from the pen delivery system. ACTIONS: In vitro and in vivo studies suggest that the biological activity of peginterferon alfa-2b is derived from its interferon alfa-2b moiety. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Studies with other interferons have demonstrated species specificity. However, certain monkey species, e.g., Rhesus monkeys, are susceptible to pharmacodynamic stimulation upon exposure to human type 1 interferons. Once bound to the cell membrane, interferon initiates a complex sequence of intracellular events that include the induction of certain enzymes. It is thought that this process, at least in part, is responsible for the various cellular responses to int Preberite celoten dokument